Circassia Pharmaceuticals plc (Circassia) is a United Kingdom-based specialty biopharmaceutical company focused on the development of immunotherapies. The Company designs immunotherapies to treat a range of common allergies and autoimmune conditions. The Company's treatment, Cat-SPIRE is in the final Phase of testing for cat allergy. Circassia's pipeline of immunotherapies is based on its ToleroMune technology. ToleroMune identifies T cell epitopes, which are short linear stretches of amino acids in allergen sequence; binds to antigen presenting cells to induce regulatory T cells and identified from blood of allergic individuals. The Company also has completed the Phase IIb study for Ragweed-SPIRE, Grass-SPIRE and House Dust Mite (HDM)-SPIRE.